Aprea Therapeutics, Inc. (APRE)
NASDAQ: APRE · Real-Time Price · USD
0.8530
-0.0370 (-4.16%)
At close: Dec 31, 2025, 4:00 PM EST
0.8501
-0.0029 (-0.34%)
After-hours: Dec 31, 2025, 6:59 PM EST
Aprea Therapeutics Stock Forecast
APRE's stock price has decreased by -75.49% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Aprea Therapeutics stock has a target of 5.00, which predicts a 486.17% increase from the current stock price of 0.85.
Price Target: $5.00 (+486.17%)
Analyst Consensus: Strong Buy
Analyst Ratings
According to 1 stock analyst, the rating for Aprea Therapeutics is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $20 → $5 | Strong Buy | Maintains | $20 → $5 | +486.17% | Dec 18, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +2,244.67% | Jan 15, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +2,244.67% | Dec 17, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +2,244.67% | Nov 18, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +2,244.67% | Oct 24, 2024 |
Financial Forecast
Revenue This Year
293.08K
from 1.50M
Decreased by -80.50%
Revenue Next Year
102.00K
from 293.08K
Decreased by -65.20%
EPS This Year
-1.70
from -2.35
EPS Next Year
-1.32
from -1.70
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 315,000 | 315,000 | ||||
| Avg | 293,077 | 102,000 | ||||
| Low | 275,380 | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -79.0% | 7.5% | ||||
| Avg | -80.5% | -65.2% | ||||
| Low | -81.7% | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.75 | -0.58 | |||
| Avg | -1.70 | -1.32 | |||
| Low | -2.27 | -2.09 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.